Mpox patient dies in Donostia after hospital infection

Mpox patient dies in Donostia after contracting bicho from roommate

A 61-year-old man admitted to Hospital Donostia has died from Mpox, according to sources from the Basque Department of Health. The infection is believed to have occurred within the hospital itself through his roommate, who has been identified as the first case in the epidemic chain. The deceased was not in a terminal stage, although he suffered from a tumor in his throat and neck, according to released data.

Osakidetza (the Basque public health service) has established a perimeter of one hundred contacts and has begun vaccinating healthcare staff who may have been exposed. So far, 25 people have been vaccinated. Mpox is a rare zoonotic disease originating from tropical rainforest regions in central and western Africa, characterized by fever, myalgia, lymphadenopathy, and a rash on the hands and face similar to chickenpox.

What is known about the so-called patient zero

The focus of concern lies not only with the death itself, but with the silence surrounding its origin. No information regarding the age, origin, or nationality of the roommate—who allegedly acted as the transmitter—has been provided. This information gap has fueled various interpretations, ranging from suspicions about hospital management to the use of the case as political ammunition in the migration debate.

Some argue that an infection within a hospital reveals a failure in isolation protocols. Countering this is the argument that Mpox has a long incubation period and non-specific initial symptoms, making it difficult to detect at emergency triage. The department has not detailed whether patient zero was isolated when they shared the room.

A repeating pattern: dying with a disease, not from it

The most frequent comparison in public discourse is to the death tolls during the pandemic. Some claim that during ELbichito-19, people with serious underlying pathologies were counted as deaths, whereas now the opposite is happening: attributing the death to Mpox despite the patient's throat and neck tumor. The department maintains that Mpox was the cause because the man was not in a terminal stage.

This distinction regarding the terminal stage is the basis for the official version. It also leaves an open question: what threshold turns a disease into the primary cause of death when an underlying oncological pathology is present? There is no definitive answer in the available information.

From clinical case to political clash

Part of the commentary has shifted toward migration, suggesting the case demonstrates the risks of immigration. This interpretation is not supported by available data: the origin of patient zero has not been confirmed, and Mpox is transmitted through close contact, not nationality. Another current of thought has focused on the sensual orientation of those infected, linking the outbreak to specific practices. Epidemiological evidence points to prolonged close physical contact as the primary route, without making the outbreak an issue of identity.

The third, more technical block, discusses whether the perimeter of one hundred contacts is sufficient or if it was established too late. Vaccinating 25 healthcare workers is a modest figure if the contact tracing expands in the coming days.

---

The case leaves three unresolved questions: the identity and status of patient zero, the complete traceability of the one hundred contacts, and the exact clinical criteria that made Mpox the cause of death. None of these have a public answer for now.